GGrantIndex
← Leaderboards

Stephen B Howell

University Of California San Diego

$14,154,440
Attributed
$14,488,026
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200517
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$14,488,026 · 13

By mechanism

R01$6,290,869 · 3
T32$5,656,287 · 1
U54$1,028,511 · 1
P30$734,892 · 1
R21$667,172 · 1
U56$76,000 · 1

Top collaborators

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Drug Resistance

Research focus

Drug ResistanceCisplatinPlatinumHomeostasisCellsCopperPharmaceutical PreparationsNeoplastic CellChemotherapeutic AgentPathway InteractionsMolecular ChaperonesMediatingCarboplatinResistanceTumorDissectionBinding (Molecular Function)Therapeutic IndexAntineoplasticsProteinsDrug DevelopmentLinkDna AdductionCancer Center

Grant awards (61)

UCSD Cancer Center Training Program in Drug Development$532,941
T32 · FY2017 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$8,394
T32 · FY2017 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$558,264
T32 · FY2016 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$517,140
T32 · FY2015 · CA · contact PI
In vivo detection and genome-wide location analysis of DNA-adducts$202,275
R21 · FY2015 · CA
UCSD Cancer Center Training Program in Drug Development$486,237
T32 · FY2014 · CA · contact PI
Control of the cellular pharmacology of the platinum-containing drugs by CTR1$294,269
R01 · FY2014 · CA · contact PI
In vivo detection and genome-wide location analysis of DNA-adducts$228,909
R21 · FY2014 · CA
Cisplatin resistance mediated by copper export pathways$217,816
R01 · FY2014 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$520,749
T32 · FY2013 · CA · contact PI
Control of the cellular pharmacology of the platinum-containing drugs by CTR1$285,904
R01 · FY2013 · CA · contact PI
In vivo detection and genome-wide location analysis of DNA-adducts$235,988
R21 · FY2013 · CA
Cisplatin resistance mediated by copper export pathways$211,079
R01 · FY2013 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$502,328
T32 · FY2012 · CA · contact PI
Control of the cellular pharmacology of the platinum-containing drugs by CTR1$304,864
R01 · FY2012 · CA · contact PI
Cisplatin resistance mediated by copper export pathways$224,552
R01 · FY2012 · CA · contact PI
Cisplatin resistance mediated by copper export pathways$64,792
R01 · FY2012 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$466,132
T32 · FY2011 · CA · contact PI
Control of the cellular pharmacology of the platinum-containing drugs by CTR1$304,990
R01 · FY2011 · CA · contact PI
Cisplatin resistance mediated by copper export pathways$224,552
R01 · FY2011 · CA · contact PI
Cisplatin resistance mediated by copper export pathways$64,671
R01 · FY2011 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$466,476
T32 · FY2010 · CA · contact PI
Control of the cellular pharmacology of the platinum-containing drugs by CTR1$315,084
R01 · FY2010 · CA · contact PI
Cisplatin resistance mediated by copper export pathways$231,497
R01 · FY2010 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$459,146
T32 · FY2009 · CA · contact PI
Imaging and Modeling Core$276,439
U54 · FY2009 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$220,473
R01 · FY2009 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$91,545
R01 · FY2009 · CA · contact PI
UCSD Cancer Center Training Program in Drug Development$436,350
T32 · FY2008 · CA · contact PI
Imaging and Modeling Core$260,629
U54 · FY2008 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$220,473
R01 · FY2008 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$24,137
R01 · FY2008 · CA · contact PI
ANALYSIS OF EXOSOMES FROM CISPLATIN RESISTANT AND SENSITIVE OVARIAN CANCER$9,756
P41 · FY2008 · RR · contact PI
UCSD Cancer Center Training Program in Drug Development$343,921
T32 · FY2007 · CA · contact PI
Imaging and Modeling Core$232,183
U54 · FY2007 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$220,473
R01 · FY2007 · CA · contact PI
ANALYSIS OF EXOSOMES FROM CISPLATIN RESISTANT AND SENSITIVE OVARIAN CANCER$6,511
P41 · FY2007 · RR · contact PI
UCSD Cancer Center Training Program in Drug Development$358,209
T32 · FY2006 · CA · contact PI
Cisplatin resistance mediated by cooper export pathways$227,058
R01 · FY2006 · CA · contact PI
Imaging and Modeling Core$129,457
U54 · FY2006 · CA · contact PI
ANALYSIS OF EXOSOMES FROM CISPLATIN RESISTANT AND SENSITIVE OVARIAN CANCER$2,039
P41 · FY2006 · RR · contact PI
ACCUMULATION OF PLATINUM IN VESICLES FROM ATP7A-EXPRESSING CELLS$2,039
P41 · FY2006 · RR · contact PI
Cisplatin resistance due to loss of DNA mismatch repair$306,770
R01 · FY2005 · CA
Cisplatin resistance mediated by cooper export pathways$231,770
R01 · FY2005 · CA
Imaging and Modeling Core$129,803
U54 · FY2005 · CA
ACCUMULATION OF PLATINUM IN VESICLES FROM ATP7A-EXPRESSING CELLS$1,080
P41 · FY2005 · RR
Cisplatin resistance due to loss of DNA mismatch repair$300,898
R01 · FY2004 · CA
Cisplatin Resistance mediated by copper export pathways$216,600
R01 · FY2004 · CA
The Center for Cancer Drug Development (C2D2)$76,000
U56 · FY2004 · CA
ACCUMULATION OF PLATINUM IN VESICLES FROM ATP7A-EXPRESSING CELLS$12,870
P41 · FY2004 · RR
Cisplatin resistance due to loss of DNA mismatch repair$295,197
R01 · FY2003 · CA
Cisplatin Resistance mediated by copper export pathways$240,752
R01 · FY2003 · CA
Cisplatin resistance due to loss of DNA mismatch repair$289,658
R01 · FY2002 · CA
Cisplatin Resistance mediated by copper export pathways$216,600
R01 · FY2002 · CA
CANCER PHARMACOLOGY$183,723
P30 · FY2002 · CA
CANCER PHARMACOLOGY$183,723
P30 · FY2002 · CA
CANCER PHARMACOLOGY$183,723
P30 · FY2002 · CA
CISPLATIN RESISTANCE DUE TO LOSS OF DNA MISMATCH REPAIR$224,725
R01 · FY2001 · CA
CANCER PHARMACOLOGY$183,723
P30 · FY2001 · CA
CANCER PHARMACOLOGY$0
P30 · FY2001 · CA
CISPLATIN RESISTANCE DUE TO LOSS OF DNA MISMATCH REPAIR$219,670
R01 · FY2000 · CA